Interestingly, it has very recently been described that BRCA1-deficient breast cancer cells are sensitised to TH5487 demonstrating a new synthetic lethal partnership between HR deficiency and OGG1 inhibition [41]. This evidence concerns the gene OGG1 and breast carcinoma.